AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Praxis Precision Medicine... (PRAX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

79.18

-1.90 (-2.34%)

At close: Feb 20, 2025, 3:59 PM

79.54

0.45%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	75
Market Cap	1.48B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-9.17
PE Ratio (ttm)	-8.63
Forward PE	n/a
Analyst	Buy

Ask	86.74
Volume	286,753
Avg. Volume (20D)	364,701
Open	80.40
Previous Close	81.08
Day's Range	76.41 - 80.57
52-Week Range	33.01 - 91.83
Beta	undefined

About PRAX

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhib...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 16, 2020

Employees 82

Stock Exchange NASDAQ

Ticker Symbol PRAX

Website https://www.praxismedicines.com

Full Company Profile

Analyst Forecast

According to 10 analyst ratings, the average rating for PRAX stock is "Buy." The 12-month stock price forecast is $128, which is an increase of 61.66% from the latest price.

Buy 90.00%

Hold 10.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Praxis Precision Medicines Inc. is scheduled to release its earnings on Mar 4, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+10.94%

Praxis Precision Medicines shares are trading high... Unlock content with Pro Subscription

11 months ago

+23.13%

Praxis Precision Medicines shares are trading higher after the company reported results from a Phase 2a proof of concept study evaluating PRAX-628 in epilepsy patients with PPR.

News

3 months ago · seekingalpha.com

Praxis Precision Medicines, Inc. (PRAX) Q3 2024 Earnings Call Transcript

Praxis Precision Medicines, Inc. (NASDAQ:PRAX ) Q3 2024 Earnings Conference Call November 6, 2024 8:00 AM ET Company Participants Dan Ferry - IR, LifeSci Communications Marcio Souza - President & CEO ...

3 months ago · zacks.com

Praxis Precision Medicines, Inc. (PRAX) Reports Q3 Loss, Misses Revenue Estimates

Praxis Precision Medicines, Inc. (PRAX) came out with a quarterly loss of $2.75 per share versus the Zacks Consensus Estimate of a loss of $2.01. This compares to loss of $2.70 per share a year ago.